EnPlusOne Biosciences Welcomes New CEO, Clare Murray, Ph.D. EnPlusOne Biosciences, Inc., a trailblazing biotechnology company pioneering enzyme-driven RNA synthesis technologies, announced today the appointment of Clare Murray, Ph.D., as its new Chief Executive Officer. The decision comes at a crucial…
Rigaku Partners with Spera Pharma to Advance Drug Development In a move poised to reshape the landscape of drug discovery and pharmaceutical development, Rigaku Corporation—a leading scientific instrumentation manufacturer—and SPERA PHARMA, Inc., a cutting-edge contract development and manufacturing organization (CDMO)—have…
Aptar Launches Study to Speed FDA Approval of SmartTrack™ Platform for Inhalers AptarGroup, Inc., a global leader in drug delivery and consumer product dispensing systems, has announced a pivotal step in the advancement of its pharmaceutical services with the initiation…
ImmunityBio Files Supplemental BLA for NMIBC and Expands ANKTIVA Access for Lymphopenia Treatment ImmunityBio, Inc. (NASDAQ: IBRX), a leading company specializing in immunotherapy, has recently made significant strides in advancing its therapeutic offerings. The company announced the completion of multiple…
n-Lorem Foundation Celebrates Five Years of Innovation for Nano-Rare Diseases In an era where access to highly specialized medical treatments is often hindered by costs, timelines, and logistical constraints, the n-Lorem Foundation stands as a unique and revolutionary force within…
New Study Exposes Harmful Effects of IRA’s ‘Pill Penalty’ on Small Molecule Drugs A recently published peer-reviewed study is shedding light on the unintended yet far-reaching consequences of the Inflation Reduction Act (IRA) on the U.S. biopharmaceutical sector—particularly in the…
Vertex’s Paul Negulescu, Ph.D., Wins 2025 Gairdner Award for Cystic Fibrosis Breakthroughs In a landmark moment for both Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and the broader scientific community, Paul Negulescu, Ph.D., Senior Vice President at Vertex, has been named a…
Amneal Pharmaceuticals Commits $1.5 Million to Support Parkinson’s Disease Patients During Awareness Month In a powerful show of solidarity with the Parkinson’s community, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a global biopharmaceutical company dedicated to improving lives through the development and…
Arcturus Therapeutics Secures FDA Fast Track Designation for ARCT-2304, a Next-Generation sa-mRNA Vaccine Targeting Pandemic Influenza A (H5N1) In a significant milestone for mRNA vaccine innovation, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a late-stage clinical biotech company pioneering messenger RNA-based…
Avanzanite Bioscience Appoints Sotiris Botozis as Managing Director for Southern Europe Amid Strategic Expansion and Unprecedented Growth Avanzanite Bioscience BV, a rapidly growing player in the European life sciences and orphan drug commercialization landscape, has announced the appointment of Sotiris…
IBL International Partners with Grifols to Develop Cutting-Edge Biomarker Panels IBL International GmbH, a Tecan Group company renowned for its expertise in specialty diagnostics, has officially announced a strategic partnership with Grifols, a global healthcare leader with a legacy in…
EU Approves Expanded Use of KAFTRIO for Cystic Fibrosis Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced a significant milestone in the ongoing fight against cystic fibrosis (CF). The European Commission (EC) has officially approved a label expansion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor),…